found Documents: 311

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Aug 2017

Chi‑Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL‑689 in Lymphoma Patients in China

1 item

Press Release London: Tuesday, August 29, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has initiated a Phase I clinical trial of HMPL‑689 in China. HMPL-689 is a novel, highly selective and potent small molecule inhib

Download Press Release (PDF)

Announcements & Press Releases, Group | 31 Jul 2017

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs

1 item

London: Monday, July 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the glob

Chi‑Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL‑689 in Lymphoma Patients in China

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs

Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma

Chi-Med to Announce 2017 Half-Year Financial Results

Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China

Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer

Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO

Chi-Med Presents Clinical Data at ASCO 2017 Annual Meeting

Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017

2016 Annual Report and Notice of Annual General Meeting

Chi-Med Appoints Weiguo Su, Chief Scientific Officer, to Board of Directors

Chi-Med to host R&D Briefings on March 29 & 30, 2017

Grant of Awards under Long Term Incentive Plan

Publication of Form 20-F for the Year Ended December 31, 2016

Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs

Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of the European Neuroendocrine Tumor Society

Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer

Chi-Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee

Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma

Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia

Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

Chi-Med Appoints Industry Veteran Karen Ferrante to Board of Directors

Chi-Med Appoints Industry Veteran Paul Carter to Board of Directors

Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer

Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China

Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium

Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China

Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting

Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)

Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

Change of Non-executive Directors

Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program

Chi-Med to Announce 2016 Half-Year Financial Results

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer

Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer

Chi-Med to Participate in Two Healthcare Investor Conferences in May

Hutchison China MediTech Limited Announces Exercise of Overallotment Option

Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689

Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market

Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients

Final Prospectus

Pricing of U.S. Public Offering of ADSs

Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs

2015 Annual Report and Notice of Annual General Meeting

Repeat of Announcement of Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

Hutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs

Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

Chi-Med initiates sulfatinib Phase II clinical trial in thyroid cancer